Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057278 · ClinicalTrials.gov registry record · Phase 2
Gabapentin in Fibromyalgia Trial (GIFT)
A Phase 2 study of Fibromyalgia, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT00057278: Completed Phase 2 study of Fibromyalgia, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
NCT00057278 is a Phase 2 study of Fibromyalgia that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The registered enrollment target is 150 participants, below the 177-participant average among 76 other Fibromyalgia trials with a reported enrollment target (15% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057278, a Phase 2 study of Fibromyalgia, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will assess the safety and effectiveness of the drug gabapentin in reducing pain associated with primary fibromyalgia.
Conditions Studied
Interventions
- DRUG gabapentin
Study Locations (3)
Massachusetts
- McLean Hospital/Harvard Medical School (must live in the Boston, MA area) - Belmont
- Newton-Wellesley Hospital (must live in the Boston, MA area) - Newton
Ohio
- University of Cincinnati College of Medicine, Department of Psychiatry (must live in the Cincinnati, OH area) - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)93 total trials
What the finished NCT00057278 record still lists
NCT00057278 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 177-participant average among 76 other Fibromyalgia trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which gabapentin is the first listed.
NCT00057278 reports a single indexed study location in Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT00057278 about?
NCT00057278 is a clinical study titled "Gabapentin in Fibromyalgia Trial (GIFT)". This study will assess the safety and effectiveness of the drug gabapentin in reducing pain associated with primary fibromyalgia.
What is the current status of trial NCT00057278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-03. Estimated completion is 2006-01.
What conditions does trial NCT00057278 study?
This clinical trial studies the following conditions: Fibromyalgia.
What interventions are being tested in trial NCT00057278?
The interventions under investigation include: gabapentin (DRUG).
Who is sponsoring clinical trial NCT00057278?
This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00057278 being conducted?
This trial has 3 study locations across Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00057278's enrollment target sits among peer trials
150 21st of 76 higher than 54 of 76 other Fibromyalgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nitrous Oxide as Treatment for Fibromyalgia
RECRUITING · Phase 2
-
Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia
COMPLETED · Phase 2
-
Dextromethorphan in Fibromyalgia
COMPLETED · Phase 2
-
Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment
COMPLETED · Phase 2
-
Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain
COMPLETED · Phase 2
-
Heart Rate Variability in Response to Metformin Challenge
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia